EAST NORRITON, Pa., May 12, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN) today provided a business update and reported its financial results for the three months ended March 31, 2011.
Neo-Urinary Conduit Bladder Cancer Trial – Clinical UpdateTengion is currently conducting an initial clinical trial of its lead product candidate, the Neo-Urinary Conduit, for use in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy). This trial is designed to assess the safety and preliminary efficacy of the Neo-Urinary Conduit, as well as to allow the clinical investigators to optimize the surgical procedure and post-surgical care by incorporating the outcomes observed in each patient into the surgical technique for subsequent patients, as necessary. To date, three patients have been enrolled and implanted in the clinical trial. Clinical investigators have made surgical modifications in an effort to address conduit patency and vascular supply. Based on clinical observations and complications to date, including events within the last week, the Company is extending its objective of reaching interim data in five patients into 2012. The Company intends to provide an updated clinical timeline after a full assessment of the clinical data and plans for subsequent patient implants with investigators, the Data Safety Monitoring Committee and the FDA.
Neo-Kidney Augment Program UpdateTengion's lead preclinical program, the Neo-Kidney Augment, is intended to prevent or delay the need for dialysis or kidney transplant by increasing functional kidney mass in patients with advanced chronic kidney disease (CKD). Patients with end stage renal disease (ESRD) have CKD which has progressed to a point of little to no kidney function and these patients require dialysis or a kidney transplant to survive. According
|SOURCE Tengion, Inc.|
Copyright©2010 PR Newswire.
All rights reserved